Vanguard Portfolio Management’s First Tracks Biotherapeutics TRAX Stock Holding History

Vanguard Portfolio Management’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11M	Buy	+546,992	New	+$10.2M	﹤0.01%	2168

Other funds holding TRAX

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management's TRAX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 546,992 shares worth $11M. The stake represents ﹤0.01% of the portfolio and ranks #2168 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Vanguard Portfolio Management held 546,992 shares of First Tracks Biotherapeutics worth $11M as of Q2 2026.
First Tracks Biotherapeutics was a new Vanguard Portfolio Management position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2168 holding.
89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.